Stock code: 688029 Stock abbreviation: Nanwei Medicine

Nanwei Medical Technology Co., Ltd

Q3 2024 Report

The board of directors and all directors of the company guarantee that there is no false record, misleading statement or material omission in the content of this announcement, and assume legal responsibility for the authenticity, accuracy and completeness of its content in accordance with the law.

Important Content Notes:

The Board of Directors, the Board of Supervisors, the directors, supervisors and senior management of the Company guarantee that the contents of the quarterly report are true, accurate and complete, and that there are no false records, misleading statements or material omissions, and bear individual and joint legal liability.

The person in charge of the company, the person in charge of accounting and the person in charge of the accounting institution (accounting supervisor) shall ensure the truthfulness, accuracy and completeness of the financial information in the quarterly report.

Whether the third quarter financial statements are audited

□ Yes √ No

1. Key financial data

(i) Key accounting data and financial indicators

Unit: Yuan Currency: RMB

From the beginning of the reporting period to the report

Item The reporting period is the same as the previous year from the beginning of the year to the end of the reporting period The end of the reporting period is compared with the previous year

Period increase and decrease Change Change in the same period

Dynamic amplitude (%) Kinetic amplitude (%)

Operating income 678,602,151.95 13.44 2,012,446,160.41 15.30

140,630,694.66 15.06 451,093,598.62 16.70 attributable to shareholders of listed companies

Net profit

attributable to shareholders of listed companies

Net net of non-recurring gains and losses 139,936,897.60 17.82 445,874,952.72 18.11

profit

Cash flow from operating activities N/A N/A 381,656,637.85 6.26

Net amount

Basic earnings per share (RMB/0.75 15.38 2.41 16.99.)

shares)

Diluted earnings per share (RMB/0.75 15.38 2.41 16.99

shares)

The weighted average return on equity was 3.75 an increase of 0.21 12.21 an increase of 0.76

(%) percentage points

Total R&D investment 41,987,560.64 23.75 111,568,259.50 8.74

R&D investment accounted for 6.19 of operating income, an increase of 0.52, a decrease of 0.54, and a decrease of 0.34

Percentage (%) percentage points

At the end of the reporting period

The end of the reporting period was the end of the previous year and the end of the previous year

Change in increment or decrease

Degree (%)

Total assets 4,566,598,060.14 4,392,673,010.22 3.96

3,731,107,640.05 3,611,919,944.60 3.30 attributable to shareholders of listed companies

Owner's Equity

Note: "The reporting period" refers to the period from the beginning of the quarter to the end of the quarter for 3 months, the same below.

(ii) Items and amounts of non-recurring gains and losses

√ Applicable □ Not applicable

Unit: Yuan Currency: RMB

Non-recurring profit and loss items Amount for the period From the beginning of the year to the end of the reporting period Description

amount

Gains and losses on disposal of illiquid assets, including accrued -82,581.29 -110,059.13

The write-off portion of the provision for impairment of assets

Government subsidies included in the current profit and loss, but with the public

The normal business of the company is closely related to and in line with the country

78,277.40 225,215.58 according to the established criteria

Yes, the policy that has a continuous impact on the company's profit and loss

Except for government subsidies

Profit or loss on entrusting others to invest or manage assets 736,357.32 5,364,250.45

Other non-operating income other than the above items 106,822.05 754,886.82

and expenditures

Less: Income tax impact 130,953.13 946,089.09

Impact of minority interests (after tax) 14,125.29 69,558.73

Total 693,797.06 5,218,645.90

The reasons should be explained for the company to identify the items not listed in the Explanatory Announcement No. 1 on Information Disclosure of Companies Offering Securities to the Public as non-recurring profit and loss items and the amount is significant, and the non-recurring profit and loss items listed in the Explanatory Announcement on Information Disclosure of Companies Offering Securities to the Public No. 1 - Extraordinary Profit and Loss as recurring profit and loss, the reasons should be explained.

□ Applicable √ Not applicable

(3) The circumstances and reasons for changes in the main accounting data and financial indicators

□ Applicable √ Not applicable

2. Shareholder information

(1) The total number of ordinary shareholders and the number of preferred shareholders whose voting rights have been restored, and the shareholding status of the top 10 shareholders

Unit: shares

At the end of the reporting period, the voting rights of ordinary shareholders at the end of the reporting period were restored

Total number of 10,354 preferred shareholders None

(if any)

Shareholdings of the top 10 shareholders (excluding shares lent through refinancing)

Contains refinancing, staking, and tokens

Shareholders hold shares held by limited loans or freezes

Name of Shareholder Nature Number of Shares Proportion Selling Conditions Restricted Shares

(%) Number of shares Number of shares

Number of shares, status, volume

domestic

Shenzhen Zhongke Merchants Venture Capital Africa 41,752,818 22.23 0 0 None 0

A limited company has a law

person

domestic

Nanjing New Micro-Invasive Enterprise Management Consulting Africa 36,766,614 19.57 0 0 N/A 0

Consult the law of the company

person

Huakang Limited Overseas 9,392,372 5.00 0 0 N/A 0

juridical person

Schroder Investment Management (Incense

Hong Kong) Ltd. - Schroders Other 5,823,634 3.10 0 0 N/A 0

Global Fund Series China A-shares

(Exchange)

National Social Security Fund 413 Group Other 3,675,459 1.96 0 0 None 0

combine

National Social Security Fund Group 113 Other 3,658,281 1.95 0 0 None 0

combine

Bank of China Limited

-Huabao CSI Medical Transactional Other 3,041,526 1.62 0 0 None 0

Open-ended index securities investment base

gold

Hong Kong Securities Clearing Company Limited Other 2,973,179 1.58 0 0 None 0

Basic Pension Insurance Fund 80 Other 2,918,376 1.55 0 0 None 0

Two combinations

Agricultural Bank of China Co., Ltd

Company-ICBC Credit Suisse Innovation Movement Other 2,370,000 1.26 0 0 None 0

Equity securities investment fund

Shareholdings of the top 10 unrestricted shareholders (excluding shares lent through refinancing)

Name of shareholder: type and number of shares

Number of unrestricted tradable shares held Class of shares Number of shares

measure

Shenzhen Zhongke Merchants Venture Capital 41,752,818 RMB ordinary shares 41,752,818

limited by shares

Nanjing New Micro Invasive Enterprise Management Consulting 36,766,614 RMB ordinary shares 36,766,614

Consulting Limited

Huakang Limited 9,392,372 RMB ordinary shares 9,392,372

Schroder Investment Management (Incense

Hong Kong) Co., Ltd. - Schroders 5,823,634 RMB ordinary shares 5,823,634

Global Fund Series China A-shares

(Exchange)

National Social Security Fund 413 Group 3,675,459 RMB ordinary shares 3,675,459

combine

National Social Security Fund Group 113 3,658,281 RMB ordinary shares 3,658,281

combine

Bank of China Limited

-Huabao CSI Healthcare Trading 3,041,526 RMB ordinary shares 3,041,526

Open-ended index securities investment base

gold

Hong Kong Securities Clearing Company Limited 2,973,179 RMB ordinary shares 2,973,179

Basic Pension Insurance Fund 80 2,918,376 RMB ordinary shares 2,918,376

Two combinations

Agricultural Bank of China Co., Ltd

Company - ICBC Credit Suisse Innovation 2,370,000 RMB ordinary shares 2,370,000

Equity securities investment fund

The above-mentioned shareholders are related or a company does not know whether the above-mentioned shareholders are related or belong to the "Acquisition Management of Listed Companies".

Persons acting in concert as specified in the Measures for Action.

Top 10 shareholders and top 10

Unlimited shareholders participate in financing without financing.

securities and refinancing business said

Ming (if any)

Shareholders holding more than 5% of the shares, the top 10 shareholders and the top 10 shareholders of unrestricted tradable shares participate in the lending of shares in the refinancing business

□ Applicable √ Not applicable

The top 10 shareholders and the top 10 shareholders of unrestricted tradable shares have changed compared to the previous period due to the refinancing loan/repayment

□ Applicable √ Not applicable

3. Other reminders

Other important information about the company's operations in the reporting period that investors need to be reminded of

√ Applicable □ Not applicable

During the reporting period, the company's related products obtained the first registration certificate in 15 countries including China, United States, Germany and Brazil, and obtained a total of 34 registration certificates

and obtained a total of 22 certificates of change of registration.

Quarterly financial statements

(i) Type of audit opinion

□ Applicable √ Not applicable

(ii) Financial statements

Consolidated balance sheet

September 30, 2024

Prepared by: Nanwei Medical Technology Co., Ltd

Unit: Yuan Currency: RMB Audit Type: Unaudited

Project September 30, 2024 December 31, 2023

Liquid asset:

Monetary funds 1,281,562,227.56 1,209,267,660.84

Settlement Provisions

Lending funds

Tradable financial assets 233,902,058.15 250.05

Derivative financial assets

Notes receivable 1,376,531.00 737,782.46

Accounts receivable 441,517,732.55 410,002,460.63

Receivables financing

Prepayments 33,110,092.54 28,399,198.08

Premiums receivable

Reinsurance receivables

Reserve for reinsurance contracts receivable

Other receivables 11,727,786.85 11,715,645.53

Where: interest receivable

Dividends receivable

Buy and sell back financial assets

Inventory 538,926,006.78 521,509,657.18

Where: data resources

Contract Assets

Assets held for sale

Non-current assets that mature within one year

Other current assets 742,984,214.68 1,109,174,925.40

Total current assets 3,285,106,650.11 3,290,807,580.17

Non-current assets:

Loans and advances are issued

Debt investment

Other debt investments

Long-term receivables

Long-term equity investment 56,257,718.23 49,705,900.65

Investment in other equity instruments 7,574,964.59 7,790,185.18

Other non-current financial assets 14,643,444.70 15,015,631.01

Investment real estate

Fixed assets 671,098,760.62 294,702,931.14

Construction in progress 148,862,351.75 363,799,657.31

Productive biological assets

Oil and gas assets

Right-of-use assets 41,141,769.22 36,076,455.58

Intangible assets 73,171,848.90 89,084,072.16

Where: data resources

Development expenditures

Where: data resources

Goodwill 174,497,411.76 177,881,930.08

Long-term amortized expenses 40,841,827.57 30,326,635.74

Deferred income tax assets 31,024,904.80 28,718,906.57

Other non-current assets 22,376,407.89 8,763,124.63

Total non-current assets 1,281,491,410.03 1,101,865,430.05

Total assets 4,566,598,060.14 4,392,673,010.22

Current Liabilities:

Short-term borrowing

Borrowing from the Central Bank

Split funds

Transactional financial liabilities

Derivative financial liabilities

Notes payable 30,406,399.00 8,385,045.21

Accounts payable 293,219,106.96 265,407,911.46

Advance receipts 1,405,081.39 1,116,560.78

Contract liabilities 28,201,386.12 70,896,927.22

Proceeds from the sale and repurchase of financial assets

Absorption of deposits and interbank deposits

Acting as an agent for the purchase and sale of securities

Acting as an agent for underwriting securities

Remuneration payable to employees 93,460,157.19 158,911,653.61

Taxes payable 53,180,996.95 46,311,648.92

Other accounts payable 172,397,449.98 78,561,410.42

Where: Interest payable

Dividend payable 93,542,250.00 -

Fees and commissions payable

Reinsurance payable

Liabilities held for sale

Non-current liabilities due within one year 13,750,500.59 10,858,097.12

Other current liabilities 2,818,659.80 9,070,710.96

Total current liabilities 688,839,737.98 649,519,965.70

Non-current liabilities:

Reserve for insurance contracts

Long-term borrowing

Bonds payable

Among them: preferred shares

Perpetual bonds

Lease liabilities 26,884,854.27 25,063,609.02

Long-term payables 37,954,410.98 39,204,410.98

Long-term payable employee compensation

Projected liabilities

Deferred income 8,570,864.55 7,273,857.30

Deferred income tax liabilities 2,060,951.95 1,452,727.02

Other non-current liabilities

Total non-current liabilities 75,471,081.75 72,994,604.32

Total liabilities 764,310,819.73 722,514,570.02

Owner's Equity (or Shareholders' Equity):

Paid-up capital (or share capital) 187,847,422.00 187,847,422.00

Other Equity Instruments

Among them: preferred shares

Perpetual bonds

Capital reserve 1,916,350,696.71 1,916,350,696.71

Less: Treasury shares 50,001,864.36 -

Other comprehensive income 5,153,670.86 6,243,621.67

Special reserves

Surplus reserve 109,690,385.48 109,690,385.48

General Risk Provisions

Undistributed profit 1,562,067,329.36 1,391,787,818.74

Equity attributable to owners of the parent company (or shareholders' rights 3,731,107,640.05 3,611,919,944.60

benefit) total

Minority interests 71,179,600.36 58,238,495.60

Total owners' equity (or shareholders' equity) 3,802,287,240.41 3,670,158,440.20

Liabilities and owners' equity (or shareholders' rights 4,566,598,060.14 4,392,673,010.22

benefit) total

The person in charge of the company: Long Xiaohui The person in charge of accounting work: Rui Chen is the person in charge of the accounting institution: Ma Zhimin

Consolidated income statement

January-September 2024

Prepared by: Nanwei Medical Technology Co., Ltd

Unit: Yuan Currency: RMB Audit Type: Unaudited

Project Q3 2024 Q3 2023

(January-September) (January-September)

1. Total operating income 2,012,446,160.41 1,745,324,768.57

Including: operating income 2,012,446,160.41 1,745,324,768.57

Interest income

Premiums earned

Fee and commission income

2. Total operating costs 1,467,685,015.45 1,293,258,893.85

Including: operating costs 651,175,548.98 627,541,330.49

Interest expense

Handling fees and commission expenses

Surrender Benefit

Net payout expense

Draw down the net amount of insurance liability reserves

Policy dividend payouts

Reinsurance costs

Taxes and surcharges 23,328,191.94 17,257,553.58

Selling expenses 465,159,798.73 382,701,595.11

Administrative expenses 249,161,760.14 226,303,203.75

R&D expenses 111,568,259.50 102,602,589.38

Financial expenses -32,708,543.84 -63,147,378.46

Among them: interest expense 2,016,604.94 528,452.81

Interest income 52,756,958.52 35,321,960.55

Add: Other income 3,456,377.66 883,346.71

Investment income (loss with "-" 15,371,554.09 18,974,195.81

columns)

Among them: 9,866,333.11 7,942,183.39 for associates and joint ventures

Investment income

Gold financing at amortized cost

Proceeds are recognized at the end of production

Exchange gains (losses are marked with "-".)

columns)

Net exposure hedging gain (loss is deprecated by "-"

number)

Fair value change gain (loss to -6,431.02 2,306,266.65

"-" sign)

Credit impairment loss (loss is based on "-" -5,049,438.24 -1,577,397.65

Fill in the columns)

Asset impairment loss (loss is marked by "-" -18,458,996.41 -14,867,047.24

Fill in the columns)

Gains on disposal of assets (losses are marked by "-" 7,295.87 31,084.12

Fill in the columns)

3. Operating profit (loss is listed with "-") 540,081,506.91 457,816,323.12

Add: Non-operating income 2,402,579.67 2,676,154.59

Less: Non-operating expenses 237,479.97 5,132,763.02

4. Total profit (total loss is filled in with "-": 542,246,606.61 455,359,714.69

columns)

Less: Income tax expense 78,213,733.65 60,283,033.24

5. Net profit (net loss is listed with "-") 464,032,872.96 395,076,681.45

(1) Classification according to business continuity

1. Net profit from continuing operations (net loss to 464,032,872.96 395,076,681.45

"-" sign)

2. Net profit from discontinued operations (net loss)

"-" sign)

(2) Classification according to ownership ownership

1. Net profit attributable to shareholders of the parent company 451,093,598.62 386,526,300.88

(Net loss is indicated with a "-" sign)

2. Minority shareholders' profit and loss (net loss is "-" 12,939,274.34 8,550,380.57

number)

6. Net after-tax of other comprehensive income -1,088,120.39 923,703.61

(1) Other comprehensive attributable to owners of the parent company -1,089,950.81 928,649.44

Net amount after tax on gains

1. Other comprehensive income that cannot be reclassified into profit or loss -212,903.19 -

benefit

(1) Re-measurement of changes in defined benefit plans

forehead

(2) Other items that cannot be converted into profit or loss under the equity method

Comprehensive income

(3) Fair value of investment in other equity instruments -212,903.19 -

fluctuation

(4) The fair value of the enterprise's own credit risk

fluctuation

2. Other comprehensive income reclassified into profit or loss -877,047.62 928,649.44

(1) Other comprehensive transferable gains and losses under the equity method

Earnings

(2) Changes in the fair value of other debt investments

(3) The reclassification of financial assets is included in other comprehensives

The amount of the combined income

(4) Other credit impairment provisions for debt investments

(5) Cash flow hedging reserves

(6) Difference in translation of foreign currency financial statements -877,047.62 928,649.44

(7) Miscellaneous

(2) Other comprehensive income attributable to minority shareholders 1,830.42 -4,945.83

net after-tax of benefits

7. Total comprehensive income 462,944,752.57 396,000,385.06

(1) Comprehensive income attributable to owners of the parent company 450,003,647.81 387,454,950.32

Total benefit

(2) Total comprehensive income attributable to minority shareholders 12,941,104.76 8,545,434.74

forehead

8. Earnings per share:

(1) Basic earnings per share (RMB/share) 2.41 2.06

(2) Diluted earnings per share (RMB/share) 2.41 2.06

The person in charge of the company: Long Xiaohui The person in charge of accounting work: Rui Chen is the person in charge of the accounting institution: Ma Zhimin

Consolidated Statement of Cash Flows

January-September 2024

Prepared by: Nanwei Medical Technology Co., Ltd

Unit: Yuan Currency: RMB Audit Type: Unaudited

Project Q3 2024 Q3 2023

(January-September) (January-September)

1. Cash flow from operating activities:

Cash received from the sale of goods and the provision of services 2,067,688,695.72 1,756,472,839.47

Net increase in customer deposits and interbank deposits

Net increase in borrowing from the central bank

Net increase in borrowing and lending to other financial institutions

Cash received from the premium of the original insurance contract

Net cash received from reinsurance business

Net increase in policyholders' savings and investments

Cash for interest, fees and commissions

Net increase in borrowed funds

Net increase in funds from repurchase operations

Net cash received from agents to buy or sell securities

Tax refunds received 4,394,561.04 5,676,603.64

Other cash received related to operating activities 37,771,416.01 28,927,964.08

Subtotal cash inflow from operating activities 2,109,854,672.77 1,791,077,407.19

Cash for goods and services 719,965,957.72 630,425,037.56

Net increase in customer loans and advances

Net increase in deposits with central banks and interbank funds

Cash payment of the original insurance contract indemnity

Net increase in funds withdrawn

Cash for interest, fees and commissions

Cash to pay policy dividends

Cash paid to and on behalf of employees 583,737,996.89 484,606,321.38

Taxes paid 153,512,865.11 118,718,619.48

Other cash paid in connection with operating activities 270,981,215.20 198,149,471.27

Subtotal cash outflow from operating activities 1,728,198,034.92 1,431,899,449.69

Net cash flow from operating activities 381,656,637.85 359,177,957.50

2. Cash flow from investment activities:

Cash received from the recovery of investments 2,276,849,108.31 961,490,693.48

Cash received from investment income 37,810,179.12 35,593,736.98

Disposal of fixed assets, intangible assets and other long-term 7,295.87 31,084.12

Net cash recovered from assets

Disposal of cash received by subsidiaries and other business units

Net gold

Receipt of other cash related to investment activities

Subtotal cash inflow from investing activities 2,314,666,583.30 997,115,514.58

Acquisition and construction of fixed assets, intangible assets and other long-term assets 222,563,892.16 208,405,081.65

Cash paid for assets

Cash paid for investments 2,144,009,791.04 2,286,331,466.91

Net increase in pledged loans

3,407,949.38 31,631,838.08 paid by subsidiaries and other business units

Net gold

Payments of other cash related to investment activities

Subtotal cash outflow from investing activities 2,369,981,632.58 2,526,368,386.64

Net cash flow from investing activities -55,315,049.28 -1,529,252,872.06

3. Cash flow from financing activities:

Cash received from absorbed investments - 2,278,253.60

Among them: the subsidiary absorbs minority shareholders' investment and receives

of cash

Cash received from borrowing - 35,000,000.00

Other cash received in connection with fund-raising activities

Subtotal cash inflows from financing activities - 37,278,253.60

Cash payments for debt repayment

Distribution of dividends, profits or interest payments 187,271,838.00 103,386,880.78

gold

Where: shares paid by subsidiaries to minority shareholders

profits, profits

Other cash payments related to fund-raising activities 59,326,150.32 6,779,693.03

Subtotal cash outflow from financing activities 246,597,988.32 110,166,573.81

Net cash flow from financing activities -246,597,988.32 -72,888,320.21

4. Effect of exchange rate changes on cash and cash equivalents -7,449,033.53 28,328,212.71

sound

5. Net increase in cash and cash equivalents was 72,294,566.72 -1,214,635,022.06

Add: Opening cash and cash equivalents balance 1,209,262,660.84 1,875,360,900.82

6. Balance of cash and cash equivalents at the end of the period 1,281,557,227.56 660,725,878.76

The person in charge of the company: Long Xiaohui The person in charge of accounting work: Rui Chen is the person in charge of the accounting institution: Ma Zhimin

The first implementation of new accounting standards or interpretations of standards from 2024 onwards involves adjustments to the financial statements at the beginning of the year in which they were first implemented

□ Applicable √ Not applicable

The announcement is hereby made.

Board of Directors of Nanwei Medical Technology Co., Ltd

October 29, 2024